About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Safety Study of AMG 228 to Treat Solid Tumors

NCT02437916·7 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Amgen

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Subject must have a pathologically documented, definitively diagnosed, advanced solid tumor
Adequate hematological, renal, hepatic, and coagulation laboratory assessments

You may not be if

Active autoimmune disease, history of autoimmune disease
Treatment with immune modulators including
Use of warfarin, factor Xa inhibitors, or direct thrombin inhibitors
Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 28 days
Major surgery within 28 days of study day 1

The record

StatusTerminated

PhasePhase 1

Taking part30

StartedApr 2015

UpdatedNov 8, 2022

Conditions

Advanced Malignancy Advanced Solid Tumors Cancer Oncology Oncology Patients+6

Where7

Research Site
La Jolla, California, United States
Research Site
New Haven, Connecticut, United States
Research Site
New York, New York, United States

Clareo Health | Safety Study of AMG 228 to Treat Solid Tumors